Sagimet BiosciencesSGMT
Market Cap: $106M
About: Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Employees: 10
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
5% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
1% less funds holding
Funds holding: 81 [Q1] → 80 (-1) [Q2]
37.3% less ownership
Funds ownership: 106.13% [Q1] → 68.83% (-37.3%) [Q2]
42% less capital invested
Capital invested by funds: $123M [Q1] → $71.5M (-$51.3M) [Q2]
98% less call options, than puts
Call options by funds: $3K | Put options by funds: $134K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
JMP Securities Jonathan Wolleben 48% 1-year accuracy 32 / 66 met price target | 876%upside $32 | Market Outperform Maintained | 15 Aug 2024 |
HC Wainwright & Co. Ed Arce 43% 1-year accuracy 60 / 140 met price target | 876%upside $32 | Buy Reiterated | 15 Aug 2024 |
Goldman Sachs Andrea Tan 43% 1-year accuracy 6 / 14 met price target | 83%upside $6 | Neutral Maintained | 1 Jul 2024 |